Drugs / CD19+CD22 CAR-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04626739 | Apr 2020 → Mar 2023 | non-Hodgkin lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19+CD22 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04626739 ↗ |
| Modality | Cell therapy | “CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma” NCT04626739 ↗ |
| Target | CD19 | “CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma” NCT04626739 ↗ |
| Target | CD22 | “CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma” NCT04626739 ↗ |